日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma

Erdafitinib治疗FGFR改变的晚期或转移性胆管癌患者

Pant, Shubham; Park, Joon Oh; Su, Wu-Chou; Loriot, Yohann; Carranza, Omar; Corassa, Marcelo; Doi, Toshihiko; Qin, Shukui; Tabernero, Josep; Prenen, Hans; Folprecht, Gunnar; Winter, Helen; Dal Molin, Graziela Z; Shen, Lin; Qian, Jiaqi; Liao, Huimin; Thomas, Shibu; Sweiti, Hussein; Triantos, Spyros; Feng, Yin-Hsun

Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

KEYNOTE-966研究中乙型肝炎病毒感染对帕博利珠单抗联合化疗治疗晚期胆道癌疗效和安全性的影响

Chan, Stephen L; Yau, Thomas; Kelley, Robin K; Finn, Richard S; Yoo, Changhoon; Furuse, Junji; Ren, Zhenggang; Klümpen, Heinz-Josef; Ozaka, Masato; Pelzer, Uwe; Arslan, Cagatay; Park, Joon Oh; Edeline, Julien; Valle, Juan W; Ueno, Makoto; Vogel, Arndt; Starkopf, Liis; Malhotra, Usha; Siegel, Abby B; Qin, Shukui

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

度伐利尤单抗联合或不联合贝伐珠单抗治疗肝细胞癌经动脉化疗栓塞术(EMERALD-1):一项多区域、随机、双盲、安慰剂对照的3期研究

Sangro, Bruno; Kudo, Masatoshi; Erinjeri, Joseph P; Qin, Shukui; Ren, Zhenggang; Chan, Stephen L; Arai, Yasuaki; Heo, Jeong; Mai, Anh; Escobar, Jose; Lopez Chuken, Yamil Alonso; Yoon, Jung-Hwan; Tak, Won Young; Breder, Valeriy V; Suttichaimongkol, Tanita; Bouattour, Mohamed; Lin, Shi-Ming; Peron, Jean-Marie; Nguyen, Quang T; Yan, Lunan; Chiu, Chang-Fang; Santos, Florinda A; Veluvolu, Anil; Thungappa, Satheesh Chiradoni; Matos, Marco; Żotkiewicz, Magdalena; Udoye, Stephanie I; Kurland, John F; Cohen, Gordon J; Lencioni, Riccardo

Cancer-associated fibroblasts expressing FSTL3 promote vasculogenic mimicry formation and drive colon cancer malignancy.

表达 FSTL3 的癌症相关成纤维细胞促进血管生成拟态形成,并驱动结肠癌恶性进展

Ying Leqian, Zhu Yini, Zhang Lu, Ji Min, Wang Meidan, Dong Lei, Yun Zhengcheng, Chen Yanping, Zhou Jingyi, Huang Chunchun, Zhang Shengwei, Yang Xuhong, Yang Hui, Huang Guichun, Qin Shukui, Xie Jinbing, Liu Lin

Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study

瑞戈非尼治疗肝细胞癌的真实世界实践(REFINE):一项前瞻性观察研究

Kim, Yoon Jun; Merle, Philippe; Finn, Richard S; Kudo, Masatoshi; Klümpen, Heinz-Josef; Lim, Ho Yeong; Ikeda, Masafumi; Granito, Alessandro; Masi, Gianluca; Gerolami, René; Cho, Sung Bum; Hsu, Chih-Hung; Huang, Yi-Hsiang; Jeng, Long-Bin; Kim, Do Young; Lin, Shi-Ming; Pinter, Matthias; Shao, Guoliang; Kato, Naoya; Kurosaki, Masayuki; Numata, Kazushi; Kuo, Kung-Kai; Mao, Yilei; Lin, Yih-Jyh; Zhu, Kangshun; Twumasi-Ankrah, Philip; Khan, Javeed; Awan, Maria; Ozgurdal, Kirhan; Qin, Shukui

China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)

中国肝癌诊疗指南(2024版)

Zhou, Jian; Sun, Huichuan; Wang, Zheng; Cong, Wenming; Zeng, Mengsu; Zhou, Weiping; Liu, Lianxin; Wen, Tianfu; Kuang, Ming; Zhang, Bixiang; Tao, Kaishan; Han, Guohong; Yan, Zhiping; Wang, Maoqiang; Liu, Ruibao; Guo, Jinhe; Zeng, Zhaochong; Liang, Ping; Ren, Zhenggang; Hou, Jinlin; Zhang, Yanqiao; Liu, Xiufeng; Pan, Hongming; Bi, Feng; Liang, Changhong; Chen, Min; Yan, Fuhua; Xu, Huixiong; Xie, Xiaoyan; Ju, Shenghong; Ji, Yuan; Yun, Jingping; Li, Zengshan; Bai, Xueli; Cai, Dingfang; Chen, Weixia; Chen, Yajin; Chen, Yongjun; Cheng, Wenwu; Cheng, Shuqun; Dai, Zhi; Dai, Chaoliu; Gao, Qiang; Guo, Rongping; Guo, Wengzhi; Guo, Yabing; Hua, Baojin; Huang, Xiaowu; Jiang, Hanyu; Jia, Weidong; Li, Qiu; Li, Tao; Li, Xiangcheng; Li, Xun; Li, Yaming; Li, Yexiong; Liang, Jun; Liang, Xiao; Ling, Changquan; Liu, Hui; Liu, Tianshu; Lu, Shichun; Lv, Guoyue; Mao, Yilei; Meng, Zhiqiang; Peng, Tao; Ren, Weixin; Shi, Guoming; Shi, Hongcheng; Shi, Ming; Song, Tianqiang; Tan, Guang; Wang, Jianhua; Wang, Kui; Wang, Lu; Wang, Wentao; Wang, Xiaoying; Wang, Zhiming; Xiang, Bangde; Xia, Jun; Xing, Baocai; Xu, Jianming; Xu, Jun; Yang, Jianyong; Yang, Xinrong; Yang, Yefa; Yang, Yunke; Yao, Xiaohong; Yin, Zhenyu; Yuan, Zhengang; Zeng, Yongyi; Zeng, Yong; Zhang, Boheng; Zhang, Leida; Zhang, Shuijun; Zhang, Ti; Zhang, Zhiwei; Zhao, Ming; Zhao, Yongfu; Zheng, Honggang; Zhou, Ledu; Zhu, Jiye; Zhu, Kangshun; Shi, Yinghong; Liu, Rong; Zhang, Lan; Xiao, Yongsheng; Yang, Chun; Wu, Zhifeng; Ding, Zhengbin; Zhu, Xiaodong; Tang, Zheng; Huang, Xiaoyong; Han, Hong; Wu, Hong; Chen, Minshan; Wang, Weilin; Li, Qiang; Cai, Jianqiang; Shen, Feng; Cai, Xiujun; Qin, Shukui; Teng, Gaojun; Fan, Jia

Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies

晚期肝细胞癌二线治疗:帕博利珠单抗:KEYNOTE-240 和 KEYNOTE-394 III 期研究的荟萃分析

Finn, Richard S; Gu, Kangsheng; Chen, Xi; Merle, Philippe; Lee, Kyung-Hun; Bouattour, Mohamed; Cao, Peiguo; Wang, Wei; Cheng, Ann-Lii; Zhu, Liangjun; Lim, Ho Yeong; Kudo, Masatoshi; Pan, Yueyin; Chang, Ting-Tsung; Edeline, Julien; Li, Wei; Yang, Ping; Li, Chen; Li, Jianfeng; Siegel, Abby B; Qin, Shukui

Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study

呋喹替尼在中国结直肠癌患者中的安全性:一项来自IV期真实世界临床实践研究的年龄亚组分析

Wang, Yi; He, Yifu; Wang, Zhiqiang; Zhong, Haijun; Niu, Zuoxing; Yang, Shujun; Zhang, Tao; Zhu, Liangjun; Shu, Yongqian; Peng, Jianjun; Song, Yan; Li, Jian; Yuan, Ying; Zhang, Haibo; Yu, Gengsheng; Hua, Yunqi; Xiao, Jianjun; Fu, Jianfei; Zheng, Yulong; Zhu, Jingyu; Xue, Hua; Luo, Xian; Shi, Michael; Su, Weiguo; Li, Jin; Qin, Shukui

First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study

帕博利珠单抗联合化疗一线治疗HER2阴性晚期胃癌:KEYNOTE-859随机3期研究的中国亚组分析

Qin, Shukui; Bai, Yuxian; Li, Jin; Pan, Hongming; Luo, Suxia; Qu, Yanli; Ye, Feng; Yang, Lin; Liu, Tianshu; Li, Wei; Chen, Xi; Yang, Jianwei; Ying, Jieer; Lin, Xiaoyan; Zhao, Lin; Liang, Xinjun; Mao, Yixiang; Guo, Run; Zuo, Yi; Bordia, Sonal; Li, Shouguo

Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study

对多纳非尼常见治疗相关不良事件及其与疗效的相关性进行分析:ZGDH3 研究的探索性分析

Bi, Feng; Qin, Shukui; Gu, Shanzhi; Bai, Yuxian; Chen, Zhendong; Wang, Zishu; Ying, Jieer; Lu, Yinying; Meng, Zhiqiang; Pan, Hongming; Yang, Ping; Zhang, Helong; Chen, Xi; Xu, Aibing; Cui, Chengxu; Zhu, Bo; Wu, Jian; Xin, Xiaoli; Wang, Jufeng; Shan, Jinlu; Chen, Junhui; Zheng, Zhendong; Xu, Li; Wen, Xiaoyu; You, Zhenyu; Ren, Zhenggang; Xu, Jianming; Du, Chengyou; Fan, Qingxia; Zhang, Longzhen; Tao, Min; Jiang, Da; Wang, Senming; Chen, Yongping; Sheng, Jifang; Zhuang, Xuelong; Wu, Jun